Gabather AB (publ)
Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more
Market Cap & Net Worth: Gabather AB (publ) (GABA)
Gabather AB (publ) (ST:GABA) has a market capitalization of $1.35 Million (Skr15.12 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #36735 globally and #596 in its home market, demonstrating a 40.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Gabather AB (publ)'s stock price Skr0.06 by its total outstanding shares 236204876 (236.20 Million).
Gabather AB (publ) Market Cap History: 2015 to 2026
Gabather AB (publ)'s market capitalization history from 2015 to 2026. Data shows change from $1.17 Billion to $1.35 Million (-48.30% CAGR).
Gabather AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Gabather AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
-4147.04x
Gabather AB (publ)'s market cap is -4147.04 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $939.08 Million | $476.27K | -$7.89 Million | 1971.74x | N/A |
| 2017 | $315.83 Million | $3.01 Million | -$9.94 Million | 104.89x | N/A |
| 2018 | $271.62 Million | $45.94K | -$20.31 Million | 5912.44x | N/A |
| 2019 | $109.49 Million | $370.00 | -$14.28 Million | 295916.75x | N/A |
| 2021 | $95.38 Million | $-23.00K | -$17.00 Million | -4147.04x | N/A |
Competitor Companies of GABA by Market Capitalization
Companies near Gabather AB (publ) in the global market cap rankings as of March 19, 2026.
Key companies related to Gabather AB (publ) by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Gabather AB (publ) Historical Marketcap From 2015 to 2026
Between 2015 and today, Gabather AB (publ)'s market cap moved from $1.17 Billion to $ 1.35 Million, with a yearly change of -48.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr1.35 Million | +133.58% |
| 2025 | Skr576.92K | -93.15% |
| 2024 | Skr8.42 Million | -71.63% |
| 2023 | Skr29.69 Million | -68.87% |
| 2022 | Skr95.38 Million | 0.00% |
| 2021 | Skr95.38 Million | -19.11% |
| 2020 | Skr117.91 Million | +7.69% |
| 2019 | Skr109.49 Million | -59.69% |
| 2018 | Skr271.62 Million | -14.00% |
| 2017 | Skr315.83 Million | -66.37% |
| 2016 | Skr939.08 Million | -20.07% |
| 2015 | Skr1.17 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Gabather AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.35 Million USD |
| MoneyControl | $1.35 Million USD |
| MarketWatch | $1.35 Million USD |
| marketcap.company | $1.35 Million USD |
| Reuters | $1.35 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.